Compare Moderna, Inc. (MRNA) vs Charles Schwab Corporation Common Stock (SCHW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs Charles Schwab Corporation Common Stock — how do they compare? Moderna, Inc. trades at $136.41 (market cap $54.14B), while Charles Schwab Corporation Common Stock trades at $106.54 (market cap $184.24B). The key difference: Charles Schwab Corporation Common Stock is far larger — about 3.4× Moderna, Inc.'s market cap, and Charles Schwab Corporation Common Stock pays a 1.2% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | SCHW | |
|---|---|---|
Market Cap | $54.14B | $184.24B |
Sector | Health | Financials |
52-Week High | $174.38 | $113.65 |
52-Week Low | $22.36 | $85.35 |
Enterprise Value | $50.29B | — |
Dividend Yield | — | 1.2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
Charles Schwab (SCHW) trades at $106.87, down 2.21% with a bearish technical signal. The stock shows strong fundamentals with Q2 2026 EPS beating expectations at $1.62 vs. $1.56 expected, continuing a trend of earnings beats. Revenue grew to $23.92B in 2025 with a robust 38.79% net income margin. Analyst consensus is bullish with 57% buy ratings and a $122.14 price target, representing 14% upside potential.
SCHW presents a compelling investment case with strong earnings momentum and expanding digital asset offerings, though near-term technical weakness and competitive pressures in the RIA custody space warrant caution. The company's diversified revenue streams and improving cash flow trends support long-term growth prospects despite current market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About Charles Schwab Corporation Common Stock
Charles Schwab operates in brokerage, banking, and asset-management businesses. The company runs a large network of brick-and-mortar brokerage branch offices, a well-established online investing website, and has mobile trading capabilities. It also operates a bank and a proprietary asset management business and offers services to independent investment advisors. The company is among the largest firms in the investment business, with over $8 trillion of client assets at the end of 2021. Nearly all of its revenue is from the United States.
Read more on SCHW →
